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Abstract
Background: Interpretation of comparative health-related quality of life (HRQOL) studies following
different prostate cancer treatments is often difficult due to differing patient ages. Furthermore, age-
related changes can hardly be discriminated from therapy-related changes. The evaluation of age-and
comorbidity-related changes was in focus of this study.
Methods:  HRQOL of 528 prostate cancer patients was analysed using a validated questionnaire
(Expanded Prostate Cancer Index Composite) before a curative treatment. Patients were divided into age
groups  ≤65, 66-70, 71-75 and >75 years. The impact of specific comorbidities and the Charlson
Comorbidity Index (CCI) were evaluated. The questionnaire comprises 50 items concerning the urinary,
bowel, sexual and hormonal domains for function and bother. For assessment of sexual and hormonal
domains, only patients without prior hormonal treatment were included (n = 336).
Results: Urinary incontinence was observed increasingly with higher age (mean function scores of 92/88/
85/87 for patients ≤65, 66-70, 71-75 and >75 years)  complete urinary control in 78%/72%/64%/58% (p <
0.01). Sexual function scores decreased particularly (48/43/35/30), with erections sufficient for intercourse
in 68%/50%/36%/32% (p < 0.01)  a decrease of more than a third comparing patients ≤65 vs. 66-70 (36%)
and 66-70 vs. 71-75 years (39%). The percentage of patients with comorbidities was lowest in the youngest
group (48% vs. 66%/68%/63% for ages 66-70/71-75/>75 years; p < 0.05). A multivariate analysis revealed
an independent influence of both age and comorbidities on urinary incontinence, specifically diabetes on
urinary bother, and both age and diabetes on sexual function/bother. Rectal domain scores were not
significantly influenced by age or comorbidities. A CCI>5 particularly predisposed for lower urinary and
sexual HRQOL scores.
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Conclusion: Urinary continence and sexual function are the crucial HRQOL domains with age-related
and independently comorbidity-related decreasing scores. The results need to be considered for the
interpretation of comparative studies or longitudinal changes after a curative treatment.
Background
The number of men diagnosed with localized prostate
cancer has increased substantially since the advent of
prostate-specific antigen (PSA) testing [1]. The incidence
rates stabilized in the last years [2]. Only one randomized
study of radical prostatectomy has shown that treatment
reduces prostate cancer mortality compared to watchful
waiting [3]. Alternatively, external beam irradiation or
interstitial brachytherapy is offered frequently [4-8].
Despite advances in the primary treatments, no rand-
omized controlled trial has proven the superiority of one
modality in terms of cancer control. In the absence of
mortality data, health-related quality of life (HRQOL)
evaluations become important outcomes.
Commonly used grading systems are suitable to deter-
mine the incidence of most serious side effects, but not
the precise significance of problems for HRQOL. Patients
are subjectively assessing their problems to be of higher
grades compared to the assessment obtained by the phy-
sician [9]. Many functions are already impaired before
treatment. Important factors are the patient age and
comorbidities. Only a minority of HRQOL studies in men
with prostate cancer provide some form of comorbidity
information [10].
Interpretation of comparative HRQOL studies following
different prostate cancer treatments is often difficult due
to differing patient ages. Patients receiving external beam
radiation therapy are usually slightly older compared to
patients receiving brachytherapy, and on average about
ten years older compared to patients treated with radical
prostatectomy [4-8]. Age-related changes can hardly be
discriminated from therapy-related changes in these stud-
ies. Not only pre-treatment HRQOL, but additionally nat-
ural HRQOL changes can be expected to differ between
these patient groups (e.g. changes of a 60 year old com-
pared to a 70 year old patient in the subsequent ten years
of life). The aim of this study was to evaluate age-related
and comorbidity-related urinary, bowel, sexual and hor-
monal HRQOL differences of prostate cancer patients
before a primary curative treatment.
Methods
This study was based on 528 consecutive patients who
were scheduled for any kind of a curative radiotherapy
treatment (external beam irradiation, temporary or per-
manent brachytherapy) due to cT1-3N0M0 prostatic car-
cinoma in the years 20032007. All patients answered a
validated questionnaire, the Expanded Prostate Cancer
Index Composite (EPIC), before the treatment [11]. The
questionnaire was handed over to the patients personally
by one of the physicians. It comprises 50 items concerning
the urinary, bowel, sexual and hormonal domains for
function and bother. The multi-item scale scores were
transformed lineary to a 0100 scale, with higher scores
representing better health-related quality of life. For a
detailed analysis, questions in the urinary domain were
classified into incontinence and irritation/obstruction
subscales [11,12].
Data has been acquired in compliance with the Helsinki
Declaration. The evaluation was approved by the local
ethics committee. Informed consent was obtained from
patients for the treatment. Patients were informed about
the voluntary participation in the evaluation of quality of
life data. An explicit statement about the voluntary char-
acter of the participation was heading every page of the
questionnaire.
The EPIC was administered in German. It has been trans-
lated in the Department of Radiation Oncology and vali-
dated in the department of Medical Psychology and
Medical Sociology of our institution [13]. Several studies
have been already published [14-20]. These studies very
well support the sensitivity of the questionnaire for qual-
ity of life changes after treatment in all domains. The rela-
tion between individual questions and quality of life
scores in different domains as well the correlation of func-
tion and bother domains or changes with time have been
elaborated in detail. In accordance with data published by
Osoba et al. [21], mean HRQOL changes of below 5
points were defined as clinically not significant. For
patients who indicated "a little" change, the mean change
in scores was about 5 to 10, for "moderate" change, about
10 to 20; and for "very much" change, greater than 20. The
EORTC (European Organization for Research and Treat-
ment of Cancer) QLQ (Quality of Life Questionnaire)-
C30, evaluated by Osoba et al., uses comparably to the
EPIC a 0 to 100 scale. Though the assessment of a clini-
cally significant threshold remains controversial, a 5-
point threshold proved likewise to be clinically significant
in our own experience [14-20].
The group has been divided into the age groups up to 65
(n = 116), 66-70 (n = 144), 71-75 (n = 158) und >75 yearsBMC Cancer 2009, 9:296 http://www.biomedcentral.com/1471-2407/9/296
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(n = 110) with the aim to discriminate purely age-related
health-related quality of life (HRQOL) changes. Five-year
increments have been estimated to be relevant intervals
with an adequate patient number in each group to detect
significant age-related differences. The Charlson Comor-
bidity Index (CCI) was calculated as a scale that considers
both comorbidities and the patient age (starting at 50
years of age, each decade is counted as an extra point)
[22].
Neoadjuvant hormonal therapy (NHT) was administered
in 192 cases. In a preliminary analysis, mean HRQOL
scores were found to be significantly lower in the sexual
(function scores: -18 points) and hormonal (function
scores: -11 points) domains. Therefore, all evaluations of
sexual and hormonal symptoms and scores were limited
to the group of patients without NHT (n = 336; i.e. pros-
tate cancer not treated with any method before).
Statistical analysis was performed using the SPSS 14.0
(SPSS, Chicago, Ill), software. To explore statistical
HRQOL score differences between different subgroups,
the Mann-Whitney-U-test was used. Contingency table
analysis with the chi-square test was performed to com-
pare treatment groups with respect to categorical varia-
bles. In a logistic forward stepwise multivariate analysis,
different risk factors were tested for their independence.
For the evaluation of age and comorbidities, multivariate
analysis was performed twice: 1. considering age and the
presence of any comorbidity; 2. considering age and vari-
ous specific comorbidities. As the CCI scale is considering
both age and comorbidities, it cannot be considered in
this multivariate analysis. Hazard ratios in dependence on
the CCI scale were therefore reported separately. The glo-
bal significance level for all statistical test procedures con-
ducted was chosen as α = 5%. All statistical analyses were
conducted in an explorative manner. Thus, with consider-
Table 1: Patient characteristics (n = 528)
≤65 years (n = 116) 66-70 years (n = 
144)
71-75 years (n = 
158)
>75 years (n = 110) significant difference
patient age, years
mean ± SD; median
62 ± 4; 63 68 ± 2; 68 73 ± 2; 73 78 ± 2; 77 all comparisons (p < 0.01)
prostate volume, cc
mean ± SD; median
42 ± 20; 35 44 ± 20; 39 45 ± 23; 40 46 ± 21; 42 -
PSA<10 ng/mL,
n (%)
66 (57) 93 (65) 95 (60) 55 (50) 66-70 vs. >75 years 
(p < 0.05)
biopsy Gleason score <7; 
n (%)
72 (62) 90 (63) 98 (62) 55 (50) 66-70 vs. >75 years 
(p < 0.05)
prior hormonal therapy; 
n (%)
46 (40) 50 (35) 55 (35) 41 (37) -
comorbidities;
n (%)
56 (48) 95 (66) 108 (68) 69 (63) ≤65 vs. 66-70/71-75/>75 
years (p < 0.05)
hypertension;
n (%)
24 (21) 44 (31) 53 (34) 27 (25) ≤65 vs. 71-75 years 
(p < 0.05)
coronary heart disease;
n (%)
17 (15) 29 (20) 43 (27) 30 (27) ≤65 vs. 71-75/>75 years 
(p < 0.05)
diabetes;
n (%)
13 (11) 16 (11) 17 (11) 16 (15) -
COPD;
n (%)
7 (6) 13 (9) 17 (11) 12 (11) -
CCI<5/5/>5;
n (%)
86/17/13 (74/15/11) 69/49/26
(48/34/18)
0/85/73
(0/54/46)
0/47/63
(0/43/57)
for all (p < 0.01), with 
exception 71-75 vs. >75
SD: standard deviation; PSA: prostate specific antigen; COPD: chronic obstructive pulmonary disease; CCI: Charlson Comotbidity IndexBMC Cancer 2009, 9:296 http://www.biomedcentral.com/1471-2407/9/296
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ation of the explorative character of the analysis, p-values
< 0.05 can be interpreted as statistically significant test
results.
Results
Patient characteristics (Table 1) demonstrate a well bal-
anced distribution of a prior hormonal therapy over the
different age groups. The prostate volume was slightly
increasing with the patient age. The highest percentage of
tumors with a PSA ≥10 ng/mL and a Gleason score ≥7 was
found in the oldest age group. The percentage of patients
with at least a single comorbidity was lowest in the young-
est age group (significant difference in comparison to all
other age groups)  four of the most frequent comorbidities
are listed additionally in Table 1. The CCI demonstrates
highly significant differences. Patients older than 70 years
reached at least five points due to their age (three points)
and the diagnosis of prostate cancer (two points).
Urinary incontinence was observed increasingly with
higher age; urinary bother scores decreased. Sexual func-
tion scores fell most impressively, but sexual bother scores
did not change as markedly (Table 2). The results of some
individual questions demonstrating significant changes
with increasing patient ages are presented in Figures 1, 2,
3 and 4 (only tendencies in the hormonal domain). Some
ability to have an erection remains even in the oldest age
group, but in only 32% firm enough for sexual inter-
course. The percentage of patients with erections firm
enough for sexual intercourse decreased more than a third
comparing patients up to 65 vs. 66-70 years (36%) and
66-70 vs. 71-75 years (39%), respectively. Even clearer
than the different age groups, a CCI>5 was particularly
predisposing for significantly lower urinary function/
bother (including both continence and irritation/obstruc-
tion) and lower sexual function/bother scores (Table 3).
The presence of even a single comorbidity was associated
with decreased HRQOL scores (Table 4). A mean decrease
of at least 5 points has not been observed in the rectal
domain. Parallel with a higher patient age, decreasing
scores associated with a comorbidity were found for the
urinary continence function, urinary bother (specifically
coronary heart disease and diabetes) and sexual function
(strong impact of diabetes). A contrary effect resulted in
the hormonal domain  decreasing scores associated with
coronary heart disease and COPD, but increasing scores
associated with age.
Table 2: Function and bother scores (mean ± standard deviation; median) in dependence on age group
≤65 years 66-70 years 71-75 years >75 years
urinary function 94 ± 13; 100 92 ± 15; 100 91 ± 14; 100 92 ± 12; 94
continence function* 92 ± 18; 100 88 ± 21; 100 85 ± 23; 100 87 ± 20; 94
irritative/obstructive function 95 ± 13; 100 97 ± 12; 100 98 ± 10; 100 98 ± 9; 94
urinary bother† 82 ± 20; 89 84 ± 20; 91 82 ± 18; 89 79 ± 19; 86
continence bother 93 ± 22; 100 90 ± 25; 100 90 ± 25; 100 90 ± 22; 100
irritative/obstructive bother 80 ± 20; 90 83 ± 20; 90 81 ± 18; 85 79 ± 18; 83
bowel function 91 ± 11; 96 93 ± 9; 96 93 ± 9; 96 93 ± 9; 96
bowel bother 93 ± 14; 100 93 ± 14; 100 95 ± 10; 100 93 ± 13; 100
sexual function‡ 48 ± 25; 50 43 ± 23; 50 35 ± 23; 32 30 ± 24; 28
sexual bother 68 ± 32; 75 64 ± 34; 75 56 ± 36; 56 60 ± 33; 63
hormonal function§ 88 ± 17; 100 91 ± 16; 100 92 ± 13; 100 95 ± 10; 100
hormonal bother 89 ± 16; 96 91 ± 15; 100 92 ± 14; 96 94 ± 11; 100
*significant difference ≤65 vs. 71-75/>75 years (p < 0.01)
† significant difference 66-70 vs. >75 years (p < 0.01)
‡ significant difference ≤65 vs. 71-75/>75 and 66-70 vs. 71-75/>75 years (p < 0.01)
§ significant difference ≤65 vs. >75 years (p = 0.03)BMC Cancer 2009, 9:296 http://www.biomedcentral.com/1471-2407/9/296
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Table 3: Function and bother scores (mean ± standard deviation; median) in dependence on Charlson Comorbidity Index (CCI)
CCI <5 5 >5
urinary function* 94 ± 12; 100 93 ± 12; 100 89 ± 16; 94
continence function* 92 ± 17; 100 90 ± 18; 100 82 ± 25; 100
irritative/obstructive function 97 ± 12; 100 97 ± 9; 100 96 ± 13; 100
urinary bother* 85 ± 19; 93 84 ± 16; 89 77 ± 22; 82
continence bother* 93 ± 20; 100 93 ± 20; 100 86 ± 29; 100
irritative/obstructive bother* 84 ± 19; 90 83 ± 16; 85 76 ± 21; 80
bowel function 93 ± 9; 96 93 ± 8; 96 91 ± 10; 96
bowel bother 94 ± 13; 100 94 ± 11; 100 92 ± 15; 100
sexual function* 49 ± 22; 51 37 ± 24; 37 31 ± 24; 29
sexual bother† 68 ± 31; 75 64 ± 34; 69 52 ± 36; 50
hormonal function 92 ± 14; 100 90 ± 13; 100 90 ± 13; 100
hormonal bother 92 ± 13; 100 90 ± 15; 96 90 ± 15; 96
*significant difference <5/5 vs. >5 (p < 0.01)
† significant difference <5 vs. >5 (p < 0.01) and 5 vs. >5 (p = 0.03)
Percentage of patients with no complete urinary control (p <  0.01) and big/moderate problem with urinary function (p =  0.04) Figure 1
Percentage of patients with no complete urinary con-
trol (p < 0.01) and big/moderate problem with uri-
nary function (p = 0.04).
Percentage of patients with at least three daily bowel move- ments (p = 0.04) and at least rare bloody stools (p = 0.02) Figure 2
Percentage of patients with at least three daily bowel 
movements (p = 0.04) and at least rare bloody stools 
(p = 0.02).BMC Cancer 2009, 9:296 http://www.biomedcentral.com/1471-2407/9/296
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The multivariate analysis (Table 5) demonstrated an inde-
pendent influence of both age and comorbidities on
incontinence, specifically diabetes on urinary bother
(obstructive/irritative symptoms), both age and diabetes
on sexual function/bother and both age and comorbidi-
ties on hormonal function (contrary effect). The patient
groups ≤70 years and >70 years had an average age of 65
and 75 years, respectively. Thus, the hazard ratio corre-
sponds on average to the symptom increase between a 65
year old and a 75 year old patient. A CCI>5 doubled the
probability for individual urinary symptoms, erectile dys-
function or a great/moderate problem with urinary or sex-
ual function overall (Table 6).
Comparing a particular group of prostate cancer patients
who were scheduled for a permanent brachytherapy as
monotherapy (n = 69) to the remaining patients (n =
459), a significantly younger patient age (mean 66 vs. 71
years; p < 0.01) and a smaller portion with comorbidities
(48% vs. 64%; p < 0.01  coronary heart disease in 10% vs.
24%: p < 0.01) became evident. HRQOL scores were sig-
nificantly higher before treatment in the urinary, sexual
and hormonal domains  with greatest mean differences (p
< 0.01 for all) considering urinary continence function/
bother (8 points respectively), obstructive/irritative
bother/overall urinary bother (9 points respectively), and
sexual function/bother (18 points respectively).
Discussion
Patient age has a strong impact on HRQOL for prostate
cancer patients before a primary curative treatment.
Increasing urinary incontinence, urinary bother, and
above all a strongly age-related decreasing sexual function
has to be considered. Comparability of studies analyzing
incontinence and impotence is often limited by different
definitions. Urinary continence can be defined by wearing
pads, dripping urine when coughing, any involuntary loss
of urine or other definitions [23-25]. In the RTOG/EORTC
(Radiation Therapy Oncology Group/European Organi-
zation for Research and Treatment of Cancer) grading sys-
tem, urinary incontinence does not occur at all [26]. LENT
SOMA (Late Effects Normal Tissues with Subjective,
Objective, Management and Analytic categories) tables
consider incontinence in some detail (e.g. grade 1 = <
weekly episodes/occasional use of pads) [27]. HRQOL
questionnaires allow an assessment with a higher accu-
racy from the patient's perspective.
Remarkable differences result between the percentage of
patients who retain some ability to have an erection with
increasing age and the percentage with erections firm
enough for intercourse. Probably the best definition of
potency (if only a single definition is used) is the ability
to have an erection sufficient for penetration. This ability
was found to decline particularly comparing the age
groups ≤65, 66-70 and 71-75 years. Sexual function scores
decreased remarkably between all age groups (mean
decrease of 18 points between the age groups ≤65 and >75
years). Older patients accept a missing potency easier, so
that changes of sexual bother scores were found to be less
impressive (mean decrease of only 8 points between the
age groups ≤65 and >75 years). Improving bother scores
for patients with low scores before external beam radio-
therapy have been shown in a recently published analysis
[20], indicating some adaptation to the sexual problems.
Percentage of patients with at least poor ability to have an  erection (p = 0.04) and erections firm enough for sexual  intercourse (p < 0.01) Figure 3
Percentage of patients with at least poor ability to 
have an erection (p = 0.04) and erections firm 
enough for sexual intercourse (p < 0.01).
Percentage of patients with daily lack of energy (p = 0.18)  and daily hot flashes (p = 0.18) Figure 4
Percentage of patients with daily lack of energy (p = 
0.18) and daily hot flashes (p = 0.18).BMC Cancer 2009, 9:296 http://www.biomedcentral.com/1471-2407/9/296
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Rectal domain scores have not been found to be age-
dependent. However, some symptoms differed between
the age groups. Older patients tend to have less frequent
bowel movements  a consequence of declining metabo-
lism and physical activity. Furthermore, the percentage of
patients who observed bloody stools is decreasing. It is
unclear, if bloody stools are actually not occurring or sim-
ply not noticed. An occasional bleeding rate of 12% in the
patient group up to 65 years is remarkable. As rectal bleed-
ing is considered an important sign of proctitis following
radiotherapy, this high frequency stresses the importance
of recording the presence of bleeding already before treat-
ment. For example, a higher bleeding rate in a patient
group with a lower dose to the rectum volume could only
be explained by a higher bleeding rate already before
treatment in a group of patients after post-prostatectomy
radiotherapy [19]. Late rectal bleeding is a key dose-limit-
ing end point in prostate radiotherapy with increasing
incidence above a dose of 60 Gy [28]. In a study by Gold-
ner et al. [29], 52 patients were reported with grade 23
EORTC/RTOG late rectal side effects  the reason was rectal
bleeding for 50 patients (96%).
Hormonal function, as defined in the EPIC questionnaire,
improved with higher patient ages. Testosterone levels are
known to decline with age. Manifestations of testosterone
deficiency include depression, irritability, weakness,
diminished libido, reduced muscle and bone mass [30].
The results of this study suggest some adaptation to
changing hormone levels. As both comorbidities and age
(contrary effects on hormonal scores) are considered in
the calculation of CCI, no effect of CCI differences was
found on hormonal scores.
As recently reported by Bhojani et al. [31], select comor-
bidities have a very strong effect on urinary function and
sexual function. In comparison to the younger patients
(≤65 years), the incidence of comorbidities was higher
with increasing age in our study. Comorbidities have an
additional, independent impact on HRQOL. Focusing on
specific comorbidities, hypertension  the most frequent
comorbidity in this population  has not been found to
influence any of the HRQOL domains. Diabetes mellitus,
a disease known to ensue microvascular complications
and neuropathy, had the strongest influence on urinary
symptoms and, above all, sexuality. Both sexual function
and sexual bother scores were affected with a mean
decrease of 16 and 18 points, respectively. Diabetes is very
well known as a predictor of late radiation morbidity
[32,33]. In contrast to studies using only various toxicity
grading scales [32,33], prospective HRQOL studies help
to consider more accurately pre-existing symptoms. Coro-
nary heart disease and independently, chronic obstructive
pulmonary disease, were associated with decreased hor-
monal domain scores. These diagnoses are very well
known to reduce normal physical activities. No correla-
Table 4: Association of health-related quality of life score decrease with comorbidities (mean ± standard deviation; only significant 
differences of at least 5 points presented)
comorbidity (n = 328/178*) coronary heart disease (n = 119/63*) diabetes (n = 62/37*) COPD (n = 49/29*)
urinary function - - - -
continence function 5 ± 2 6 ± 2 7 ± 3 -
irritative/obstructive function - - - -
urinary bother 6 ± 2† 7 ± 2† 9 ± 3† -
continence bother - - - -
irritative/obstructive bother 5 ± 2† 6 ± 2† 8 ± 3† -
sexual function 9 ± 3† - 16 ± 4† -
sexual bother 10 ± 4 - 18 ± 6† -
hormonal function 5 ± 2† 7 ± 2† - 5 ± 3†
hormonal bother 5 ± 2† 6 ± 2† - 5 ± 3†
COPD: chronic obstructive pulmonary disease
*patients without a prior hormonal therapy (analysis of sexual and hormonal domains)
† p < 0.01BMC Cancer 2009, 9:296 http://www.biomedcentral.com/1471-2407/9/296
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Table 6: Hazard ratios for individual symptoms with a Charlson Comorbidity Index of >5 vs. ≤5
question hazard ratio 95% confidence interval p-value
leaking urine ≥once a day 2.5 1.54.0 < 0.01
no complete urinary control 1.7 1.22.5 < 0.01
great/moderate problem with frequent urination 2.1 1.33.2 < 0.01
great/moderate problem with urinary function overall 2.1 1.33.2 < 0.01
erections not firm enough for intercourse 2.2 1.34.0 < 0.01
great/moderate problem with sexual function overall 2.2 1.23.8 < 0.01
COPD: chronic obstructive pulmonary disease
Table 5: Multivariate analysis considering the influence of age (>70 vs. ≤70 years) and comorbidities (1. any comorbidity, 2. specific 
comorbidities) on individual symptoms
question risk factor hazard ratio 95% confidence interval p-value
leaking urine ≥once a day comorbidity 2.2 1.23.8 < 0.01
coronary heart disease 1.7 1.02.9 0.06
diabetes 1.9 1.03.7 0.06
no complete urinary control age 1.9 1.32.7 < 0.01
great/moderate problem with frequent urination comorbidity 2.0 1.23.3 < 0.01
diabetes 3.3 1.95.9 < 0.01
great/moderate problem with urinary function overall comorbidity 2.2 1.23.9 < 0.01
diabetes 2.5 1.34.8 < 0.01
erections not firm enough for intercourse age 2.8 1.74.7 < 0.01
comorbidity 1.7 1.02.9 0.04
diabetes 7.0 2.321 < 0.01
great/moderate problem with sexual function overall age 1.8 1.13.7 0.04
comorbidity 1.9 1.13.5 0.03
diabetes 2.9 1.36.2 < 0.01
hot flashes ≥once a day comorbidity 3.5 1.012 0.05
COPD 5.6 1.916 < 0.01
lack of energy ≥once a day age 0.4 0.21.0 < 0.05
comorbidity 4.2 1.412 0.01
great/moderate problem with hot flashes COPD 4.5 1.513 < 0.01
great/moderate problem with lack of energy comorbidity 2.7 1.16.4 0.03
COPD: chronic obstructive pulmonary diseaseBMC Cancer 2009, 9:296 http://www.biomedcentral.com/1471-2407/9/296
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tion of comorbidities, similar to the patient age, was
found with the rectal domain scores.
Conclusion
Urinary continence and sexual function are the crucial
HRQOL domains with age-related and independently
comorbidity-related decreasing scores. Diabetes, not
found to increase significantly with age in this popula-
tion, was found to have the greatest impact on the urinary
and above all on the sexual domain. The results need to
be considered for the interpretation of studies comparing
different primary treatments or longitudinal changes after
a curative treatment.
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